Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-26 | Wendy Perrow has served as a member of our board of directors since January 2022. She serves as a Senior Advisor at Princeton Capital Advisors, a global independent advisory firm, and she is a member of the board of advisors for the Maryland Momentum Fund. Previously, she served as Chief Executive Officer and Board Member of AsclepiX Therapeutics, Inc. from 2016 to 2020. She was the Vice President of Marketing and then Chief Executive Officer of Alba Therapeutics, Inc. from 2008 to 2016. Previously, she served as Vice President, Marketing & Sales for Sigma-Tau Pharmaceuticals focusing on rare and orphan disease products. She also held positions with Merck & Co. in U.S. and global marketing, where she led U.S. and global launches/initiatives for Zocor®, Varivax®, Cozaar®, and Hyzaar®. Ms. Perrow began her career in a division of the Johnson & Johnson Company. Ms. Perrow also serves as member of the Maryland Life Sciences Advisory Board, the Maryland TEDCO review board of the Maryland Innovation Initiative, and Women in Bio. Ms. Perrow is a graduate of Duke University, The Fuqua School of Business with an MBA and Eastern Illinois University with a BS in Education. |
| 2023-05-15 | Wendy Perrow has served as a member of our board of directors since January 2022. She serves as a Senior Advisor at Princeton Capital Advisors, a global independent advisory firm, and she is a member of the board of advisors for the Maryland Momentum Fund. Previously, she served as Chief Executive Officer and Board Member of AsclepiX Therapeutics, Inc. from 2016 to 2020. She was the Vice President of Marketing and then Chief Executive Officer of Alba Therapeutics, Inc. from 2008 to 2016. Previously, she served as Vice President, Marketing & Sales for Sigma-Tau Pharmaceuticals focusing on rare and orphan disease products. She also held positions with Merck & Co. in U.S. and global marketing, where she led U.S. and global launches/initiatives for Zocor®, Varivax®, Cozaar®, and Hyzaar®. Ms. Perrow began her career in a division of the Johnson & Johnson Company. Ms. Perrow also serves as member of the Maryland Life Sciences Advisory Board, the Maryland TEDCO review board of the Maryland Innovation Initiative, and Women in Bio. Ms. Perrow is a graduate of Duke University, The Fuqua School of Business with an MBA and Eastern Illinois University with a BS in Education. |
| 2023-08-07 | Wendy Perrow Consists of 14,167 shares issuable upon exercise of outstanding stock options that are exercisable within 60 days of July 28, 2023, of which all are vested as of such date. |
| Filing Date | Source Excerpt |
|---|---|
| 2016-01-28 | Wendy Perrow was elected as a director of the Company on December 10, 2015. Ms. Perrow is President and Chief Executive Officer at Alba Therapeutics... Ms. Perrow brings knowledge and insight of the pharmaceutical industry as well as management expertise. ... Compensation for non-employee directors during fiscal 2015 consisted of the following: ... Wendy Perrow was elected as a director and member of the Compensation Committee on December 10, 2015. ... No compensation listed for Wendy Perrow in fiscal 2015. |
| 2017-01-30 | Wendy Perrow was elected as a director of the Company on December 10, 2015. Ms. Perrow is Chief Executive Officer at AsclepiX Therapeutics. Ms. Perrow joined AsclepiX Therapeutics in 2016 as Chief Executive Officer. Prior to joining AsclepiX Therapeutics, Ms. Perrow was Chief Executive Officer at Alba Therapeutics and held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing and Sales for Sigma-Tau Pharmaceuticals, Inc. From 1989 to 2003, Ms. Perrow held positions at Merck and Co., Inc. in marketing, marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. Ms. Perrow holds a bachelor’s degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business. Ms. Perrow provides our Board of Directors with insight and perspective on marketing and leadership, stemming from her extensive experience and leadership in the pharmaceutical industry. The following table shows information regarding the compensation of BASi's non-employee directors for fiscal 2016. Wendy Perrow Fees paid in cash ($) 11,625 All Other Compensation ($) 285 Total ($) 11,910 |
| 2018-01-26 | Wendy Perrow was elected as a director of the Company on December 10, 2015. Ms. Perrow is Chief Executive Officer at AsclepiX Therapeutics... Ms. Perrow holds a bachelor’s degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business. Ms. Perrow provides our Board of Directors with insight and perspective on marketing and leadership... The Board of Directors has established Compensation, Audit and Nominating/Corporate Governance Committees. ... Compensation Committee members include Wendy Perrow (Chair) ... Audit Committee members include Wendy Perrow ... Nominating / Corporate Governance Committee members include Wendy Perrow ... DIRECTOR COMPENSATION FOR FISCAL 2017 ... Wendy Perrow ... Total ($) 18,963 |
| 2019-01-28 | Wendy Perrow was elected as a director of the Company on December 10, 2015. ... The Board of Directors has established Compensation, Audit and Nominating/Corporate Governance Committees. ... Compensation Committee: Wendy Perrow (Chair) ... Audit Committee: Wendy Perrow ... Nominating/Corporate Governance Committee: Wendy Perrow ... The following table shows information regarding the compensation of BASi's non-employee directors for fiscal 2018. ... Wendy Perrow Fees paid in cash ($) 20,000, Option Awards ($) 15,200, All Other Compensation ($) 427, Total ($) 35,627. |
| 2020-01-28 | The Board of Directors has determined that ... Wendy Perrow have no relationship with the Company that would interfere with the exercise of independent judgment... The following table shows information regarding the compensation of BASi's non-employee directors for fiscal 2019. ... Wendy Perrow Fees paid in cash ($) 29,375, Option Awards ($) 10,500, All Other Compensation ($) 1,115, Total ($) 40,990. ... Committees: Compensation (Chair), Audit. |
| 2021-01-28 | Wendy Perrow’s term on the Board of Directors ended as of the 2020 Annual Meeting of Shareholders. She received $17,500 in cash fees in fiscal 2020. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22